NEW publication on the analytical performance of Papilloplex HR-HPV
The accurate detection and genotyping of high-risk human papillomavirus (HR-HPV) is critical for cervical cancer screening and epidemiological investigations. GeneFirst Papilloplex® HRHPV is a new CE-IVD marked real-time PCR test, based on patented Multiplex Probe Amplification (MPA) technology. Papilloplex® HR-HPV provides the simultaneous detection and differentiation of 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68a/b) in a single closed-tube reaction ensuring rapid, cost effective and contamination free results. In this study, the analytical performance characteristics in terms of the assay’s sensitivity, specificity, range, reproducibility and cross-reactivity were evaluated. Papilloplex® HR-HPV provided sensitive detection and differentiation of 14 HR-HPV types with highly reproducible results. The differential HR-HPV specificity and sensitivity was further confirmed through the participation in the WHO HPV Laboratory Network Proficiency Study (2014). Overall, GeneFirst Papilloplex® HR-HPV assay demonstrated a robust analytical performance with reproducible and reliable results in the detection of HR-HPV genotypes.